OMLYCLO

This brand name is authorized in Estonia, France, Italy, Lithuania

Active ingredients

The drug OMLYCLO contains one active pharmaceutical ingredient (API):

1 Omalizumab UNII 2P471X1Z11 - OMALIZUMAB

Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Omalizumab binds to IgE and prevents binding of IgE to FcεRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of FcεRI receptors on basophils. Read about Omalizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R03DX05	Omalizumab	R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3074879, 3075027, 3075038, 3075049
Country: FR	Base de données publique des médicaments	Identifier(s): 66107946, 69603381
Country: IT	Agenzia del Farmaco	Identifier(s): 051249011, 051249023, 051249035, 051249047
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1099866, 1099867, 1099868, 1099869